Pamrevlumab (FG-3019) targets connective tissue growth factor (CTGF), which promotes muscle fibrosis and reduces the ability of damaged muscle cells to repair. Pamrevlumab binds to CTGF and may prevent this cascade. It it thought that treatment with pamrevlumab may slow the loss of muscle function.
There are currently no trials for Pamrevlmab.
This program is sponsored by FibroGen, Inc.
FEBRUARY 2022 | Webinar: FibroGen DMD Pamrevlumab Phase 3 Clinical Studies HighlightPPMD and FibroGen hosted a webinar on February 2, 2022 for a presentation discussing the clinical rationale for the use of Pamrevlumab by highlighting its Phase 2 study in non-ambulatory participants with Duchenne and provided an update on its Phase 3 094 study in ambulatory participants with Duchenne. |
JUNE 2021 | FibroGen Presents at the PPMD 2021 Virtual Annual ConferencePre-recorded content for PPMD's 2021 Virtual Annual Conference On-Demand Library |
JUNE 2019 | FibroGen Presents at the PPMD 2019 Annual Conference |
JUNE 2018 | FibroGen Presents at the PPMD 2018 Annual Conference |
OCTOBER 2017 | Webinar: FibroGen Update on Pamrevlumab & Enrolling Non-Ambulatory StudyPPMD and FibroGen hosted a webinar on October 25, 2017 to hear a community update on FibroGen’s development of Pamrevlumab and enrolling FGCL-3019-079 non-ambulatory study in Duchenne. |
FEBRUARY 2017 | Webinar: Mission DMD: FibroGen’s Anti-Fibrosis ProgramOn February 1, 2017, PPMD and FibroGen hosted a webinar to discuss FibroGen’s investigational drug Pamrevlumab (FG-3019), along with FibroGen’s Mission DMD program that is being conducted to investigate Pamrevlumab in Duchenne. |
